Background: Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and has shown clinical efficacy in preclinical models of glioblastoma. The aim of this study is to explore the addition of ipilimumab to standard therapy in patients with glioblastoma.

Methods/design: Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. Planned accrual is 120 patients (Arm A: 80, Arm B: 40). Endpoints include overall survival, 18-month survival, 5-year survival, and adverse events. The trial is currently recruiting in seven centres in the United Kingdom.

Trial Registration: ISRCTN84434175. Registered 12 November 2018.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068928PMC
http://dx.doi.org/10.1186/s12885-020-6624-yDOI Listing

Publication Analysis

Top Keywords

phase open
8
open label
8
label randomised
8
randomised study
8
study ipilimumab
8
ipilimumab temozolomide
8
versus temozolomide
8
surgery chemoradiotherapy
8
chemoradiotherapy patients
8
patients diagnosed
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!